CAS: 22204-91-7; (1-Methylpiperidin-4-yl) 2,2-Bis(4-Chlorophenoxy)Acetate

该化合物是主要用作脂质调节剂的药物化合物,属于纤维化物类,众所周知,它能够降低三重血压水平,增加血液中高密度脂蛋白胆固醇(HDL),通过激活过氧化性扩散活性受体(PPPARs)功能,在脂肪代谢中起着关键作用;该化合物通常以口服方式施用,并经常向患有心血管病或心血管疾病风险的病人开具;在管理脂肪特征方面,它是一种宝贵的治疗疗法选择,旨在降低甲状腺硬化和相关条件的风险; 利菲布拉底一般都受到良好的调用,但与其他纤维化剂一样,它可能具有副作用,包括胃肠紊乱和与其他药物的潜在互动作用; 与任何药物一样,它对于病人在使用利菲拉底期间咨询医疗专业人员进行个人咨询和监测至关重要.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-12427148-B2
    优先权日:2018-04-28
    标 题:Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
    发明人:RUGGERO DAVIDE; NGUYEN HAO; CARROLL PETER; CONN CRYSTAL
    权利人:UNIV CALIFORNIA
    摘要:In cancers such as prostate cancer, the combination of PTEN loss and activation of Myc activates an adaptive stress response that enables tumor cells to escape the stress of massively upregulated protein synthesis. This pro-survival response is mediated by the PERK-phosphorylated eIF2α axis of the UPR adaptive response. Agents that disrupt PERK-eIF2α pathways disrupt the adaptive response and lead to cancer cell death from uncontrolled growth. For example, ISRIB and derivatives may be employed as therapeutic agents to disrupt PERK-mediated adaptive mechanisms. Additionally PTEN loss and activation of Myc provides a diagnostic marker that enables better prognosis and the selection of amenable treatments.

    专利号:CN-101974034-B
    优先权日:2010-10-18
    标题 :Synthesis of Flavonoid Alkyl Phosphate Compounds and Their Application in Cholesterol Esterase Inhibitors

    专利号:CN-101974034-A
    优先权日:2010-10-18
    标 题 :Synthesis of Flavonoid Alkyl Phosphate Compounds and Their Application in Cholesterol Esterase Inhibitors

    专利号:US-2014315720-A1
    优先权日:2012-10-24
    标 题 :Polysaccharide ester microspheres and methods and articles relating thereto
    发明人:FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY
    权利人:CELANESE ACETATE LLC
    摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Percy AK, Moore JF, Waechter CJ. Phosphoglyceride biosynthesis by brain microsomes: centrophenoxine, SaH-42-348, and DH-990 inhibit phospholipid N-methylation. Arch Biochem Biophys. 1984 Nov 15;235(1):18-25.

    合成参考文献


    参考文献:10.1124/mol.119.115964
    摘要:Lee TD, Lee OW, Brimacombe KR, Chen L, Guha R, Lusvarghi S, Tebase BG, Klumpp-Thomas C, Robey RW, Ambudkar SV, Shen M, Gottesman MM, Hall MD. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology. 2019 Nov;96(5):629–40. doi: 10.1124/mol.119.115964.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知